AnnaMaria DeSalva is chairman and chief executive officer of Hill+Knowlton Strategies. She previously served as senior advisor to the chief executive of DowDuPont, and as DuPont’s chief communications officer. Prior to DuPont, Ms. DeSalva was head of corporate affairs for biopharmaceutical innovation at Pfizer, an advisor to the U.S. Food and Drug Administration, and head of the global healthcare practice of Hill & Knowlton. Earlier, at Bristol-Myers Squibb, she led global public affairs for the oncology business and served as director of the Bristol-Myers Squibb Foundation. Ms. DeSalva is a member of the board of governors of Argonne National Laboratory of the U.S. Department of Energy and serves on the compensation and nominating committees. Additionally, she serves on the boards of the non-profit Project Sunshine and the William & Mary Alumni Association, and is a member of the Economic Club of New York. Ms. DeSalva graduated from The College of William & Mary in Virginia. She has completed the Harvard School of Public Health’s executive education program in risk communication, and the Advanced Health Leadership Program jointly offered by the University of California, Berkeley and Pompeu University in Spain.